Market Access Understanding the evolution of container closure integrity t... At different stages of the drug lifecycle, the minimum provision for parenteral products is a safety barrier against potential contaminants.
Partner Content Partner Content Industry Gathers Next Week at Pharmaceutical Microbiology Ea... Last chance to register
Partner Content Partner Content The Power of Partnerships: Meeting Pharmaceutical Logistic E... Partnerships in the Supply Chain
Events Partner Content SMi's 12th annual Cold Chain Distribution Conference and Exh... This year's event will continue to lead.
News EnteroBiotix cues up larger trial of microbiome IBS therapy EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microbiome species.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl